Edition:
United States

miRagen Therapeutics Inc (MGEN.OQ)

MGEN.OQ on NASDAQ Stock Exchange Capital Market

6.95USD
18 Jul 2018
Change (% chg)

$-0.21 (-2.93%)
Prev Close
$7.16
Open
$7.20
Day's High
$7.25
Day's Low
$6.75
Volume
52,271
Avg. Vol
66,623
52-wk High
$15.23
52-wk Low
$5.01

Latest Key Developments (Source: Significant Developments)

Miragen Announces Interim Data From Phase 1 Trial Of Cobomarsen In Mycosis Fungoides
Tuesday, 8 May 2018 04:05pm EDT 

May 8 (Reuters) - miRagen Therapeutics Inc ::MIRAGEN THERAPEUTICS ANNOUNCES NEW INTERIM DATA FROM PHASE 1 CLINICAL TRIAL OF COBOMARSEN IN MYCOSIS FUNGOIDES.MIRAGEN THERAPEUTICS INC - COBOMARSEN CONTINUED TO BE GENERALLY WELL TOLERATED AT ALL DOSE LEVELS EVALUATED.MIRAGEN THERAPEUTICS ANNOUNCES NEW INTERIM DATA FROM PHASE 1 CLINICAL TRIAL OF COBOMARSEN IN MYCOSIS FUNGOIDES.  Full Article

Miragen Therapeutics Reports Qtrly ‍loss Per Share $0.29​
Wednesday, 14 Mar 2018 04:05pm EDT 

March 14 (Reuters) - Miragen Therapeutics Inc ::MIRAGEN THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.MIRAGEN THERAPEUTICS INC QTRLY ‍LOSS PER SHARE $0.29​.MIRAGEN THERAPEUTICS INC - ‍INTENDS TO INITIATE A PHASE 2 CLINICAL TRIAL FOR COBOMARSEN IN PATIENTS WITH CTCL IN SECOND HALF OF 2018​.  Full Article

Miragen Therapeutics Prices Public Offering Of Common Stock
Thursday, 8 Feb 2018 06:45pm EST 

Feb 8 (Reuters) - Miragen Therapeutics Inc ::MIRAGEN THERAPEUTICS, INC. PRICES PUBLIC OFFERING OF COMMON STOCK.MIRAGEN THERAPEUTICS INC <- ‍PRICING OF UNDERWRITTEN PUBLIC OFFERING OF 7 MILLION SHARES OF ITS COMMON STOCK AT A PUBLIC OFFERING PRICE OF $5.50 PER SHARE​.  Full Article

miRagen Therapeutics Announces Proposed Public Offering Of Common Stock
Monday, 5 Feb 2018 06:05am EST 

Feb 5 (Reuters) - Miragen Therapeutics Inc ::MIRAGEN THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.SAYS OFFERING 7.00 MILLION COMMON SHARES.MIRAGEN THERAPEUTICS - TO USE PROCEEDS FROM OFFERING FOR WORKING CAPITAL PURPOSES INCLUDING FUNDING OF PRODUCT CANDIDATES​' CLINICAL DEVELOPMENT.  Full Article

Miragen says MRG-106 continued to be generally well-tolerated at all dose levels
Monday, 11 Dec 2017 04:05pm EST 

Dec 11 (Reuters) - Miragen Therapeutics Inc ::MIRAGEN THERAPEUTICS INC - ANNOUNCED NEW INTERIM RESULTS FROM PHASE 1 CLINICAL TRIAL OF MRG-106 IN PATIENTS WITH MYCOSIS FUNGOIDES (MF) FORM OF CTCL.MIRAGEN THERAPEUTICS INC - MRG-106 CONTINUED TO BE GENERALLY WELL-TOLERATED AT ALL DOSE LEVELS EVALUATED AS OF DECEMBER 4, 2017.MIRAGEN THERAPEUTICS INC - INITIATED DOSING IN THREE ADDITIONAL ONCOLOGY INDICATIONS.MIRAGEN THERAPEUTICS INC - PLAN TO INITIATE A CONTROLLED PHASE 2 TRIAL IN H2 2018 TO FURTHER EVALUATE POTENTIAL OF MRG-106.  Full Article

Miragen Therapeutics reports third quarter financial results
Wednesday, 8 Nov 2017 04:05pm EST 

Nov 8 (Reuters) - Miragen Therapeutics Inc :Miragen Therapeutics reports third quarter 2017 financial results and provides corporate update.Q3 revenue $1.6 million versus $900,000.Q3 revenue view $306,000 -- Thomson Reuters I/B/E/S.Miragen Therapeutics Inc - ‍cash and cash equivalents at september 30, 2017 were $42.8 million, compared to $22.1 million at December 31, 2016​.Miragen Therapeutics Inc - qtrly ‍net loss per share, basic and diluted $0.27​.  Full Article

Miragen Therapeutics Q2 loss per share $0.34
Friday, 11 Aug 2017 04:05pm EDT 

Aug 11 (Reuters) - Miragen Therapeutics Inc :Miragen Therapeutics reports second quarter 2017 financial results and provides corporate update.Q2 loss per share $0.34.Q2 revenue $700,000 versus $1.1 million.Miragen Therapeutics Inc - expects that its current cash and cash equivalents will be sufficient to fund its operations through end of 2018.  Full Article

Miragen Therapeutics announces new data from phase 1 clinical trial evaluating MRG-106
Monday, 5 Jun 2017 07:00am EDT 

June 5 (Reuters) - Miragen Therapeutics Inc ::Miragen Therapeutics presents new data from phase 1 clinical trial evaluating MRG-106 in subjects with Mycosis Fungoides.MRG-106 has been generally well-tolerated to date.Only one grade 3 adverse event, Pruritus (itchy skin), was considered potentially related to MRG-106 administration.  Full Article

miRagen Therapeutics reports Q1 revenue $500,000
Wednesday, 10 May 2017 04:05pm EDT 

May 10 (Reuters) - miRagen Therapeutics Inc :miRagen Therapeutics reports first quarter 2017 financial results and provides corporate update.Q1 loss per share $0.60.Q1 revenue $500,000 versus $900,000.miRagen Therapeutics Inc says MRG-106 clinical data to be presented at ASCO in June 2017.miRagen Therapeutics Inc says cash balance sufficient to fund operations through 2018.  Full Article

Servier and Miragen extend collaboration for research
Wednesday, 3 May 2017 07:00am EDT 

May 3 (Reuters) - Miragen Therapeutics Inc :Servier and Miragen extend collaboration for research, development and commercialization of microrna-targeting therapeutics.  Full Article

BRIEF-Miragen Therapeutics Reports Q1 Loss Per Share $0.18

* MIRAGEN THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE